跳到正文
BioPharm International·· 3 天前AI 评分13

应用说明:在线浊度测量用于监测细胞培养收获液的澄清效率

Application Note - In-line Turbidity Measurement to Monitor Clarification Efficiency in Cell Culture Harvests

AI 导读

一篇应用说明聚焦在线浊度测量在细胞培养收获液澄清效率监测中的应用。原文未给出具体机构、药品、文件编号、版本或批次信息。

正文 · 原文

News|Articles|November 19, 2026

Related to this article

Q&A with Dr. Mazen Noureddin: Once-Monthly Efimosfermin and Fibrosis Improvement in MASH

November 19th, 2026

Mazen Noureddin, MD, MHSc, of Houston Methodist Hospital discusses phase 2 data for GSK's once-monthly FGF21 analog efimosfermin presented at The Liver Meeting 2026 and what the findings mean for ongoing phase 3 trials in MASH and compensated cirrhosis.

Read more

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics

November 19th, 2026

Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.

Read more

Why dMMR Rectal Tumors Respond to PD-1 Blockade Alone, Says MSK's Andrea Cercek

November 19th, 2026

In the first part of a two-part interview, Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center explains which early patient responses led to the dostarlimab study behind Jemperli's rectal cancer approval, and why mismatch repair-deficient tumors are so visible to the immune system.

Read more

Side-profile illustration of a human neck in blue and purple, with the throat and windpipe highlighted in glowing pink and red and the spine visible behind them, against a dark background. | Image Credit: © G.Go - stock.adobe.com

November 19th, 2026

Updated phase 1 data for micvotabart pelidotin, an antibody-drug conjugate that targets a protein in the tumor extracellular matrix, support Pyxis Oncology’s plan to start a phase 3 trial in recurrent/metastatic head and neck squamous cell carcinoma in mid-2027.

Read more

Molecule of mRNA, 3D illustration | Image credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com

November 19th, 2026

Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.

Read more

Three-dimensional illustration of pink Y-shaped antibodies attached to the surface of a blue cell with a ruffled, uneven surface, with similar blurred cells in the background. | Image Credit: © peterschreiber.media - stock.adobe.com

November 19th, 2026

DISCO Pharmaceuticals will receive $40 million upfront, with up to $2.5 billion in potential milestones, to discover bispecific therapeutics for AbbVie that recognize pairs of tumor surface proteins, an approach intended to limit toxicity in healthy tissue.

Read more

Chain of amino acid or bio molecules called protein - 3d illustration | Image credit: © Christoph Burgstedt - © Christoph Burgstedt - stock.adobe.com

November 19th, 2026

A second cereblon E3 ligase modulator from the Evotec and Bristol Myers Squibb degrader partnership is set to begin phase 1 testing in 2027.

Read more

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T

November 18th, 2026

Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.

Read more

来源:BioPharm International · biopharminternational.com